MirimGENE Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
MirimGENE General Information
Description
Developer of immunity drugs intended to offer personalized precision medicine to treat infectious diseases. The company targets a new endogenous immune activation factor network to develop innovative new drugs that can treat infectious diseases with no treatment and high mortality and intractable immune diseases that are resistant to existing drugs, enabling medical practitioners to treat patients who cannot be treated with existing treatments.
Contact Information
Website
www.mirimgene.comCorporate Office
- 155 Gaetbeol-ro
- Room S215, Yeonsu-gu
- Incheon
- South Korea
Corporate Office
- 155 Gaetbeol-ro
- Room S215, Yeonsu-gu
- Incheon
- South Korea
MirimGENE Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 3. Early Stage VC (Series A) | 01-Aug-2021 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Oct-2020 | $170K | $170K | Completed | Startup | |
| 1. Seed Round | 31-Aug-2020 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
MirimGENE Patents
MirimGENE Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4835063-A1 | Novel anti-tuberculosis engineered protein, and use thereof | Pending | 26-Dec-2023 | ||
| WO-2025143797-A1 | Novel anti-tuberculosis engineered protein, and use thereof | Inactive | 26-Dec-2023 | ||
| EP-4516812-A1 | Anti-wars1 antibody and use thereof | Pending | 27-Apr-2022 | ||
| EP-4516812-A4 | Anti-wars1 antibody and use thereof | Pending | 27-Apr-2022 | ||
| US-20250289905-A1 | Anti-wars1 antibody and use thereof | Pending | 27-Apr-2022 | C07K16/40 |
MirimGENE Signals
MirimGENE Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Honest Ventures | Venture Capital | Minority | ||
| KDB Capital | PE/Buyout | Minority | ||
| L&S Venture Capital | Venture Capital | Minority | ||
| Magna Investment (Seoul) | Venture Capital | Minority | ||
| Samho Green Investment | Venture Capital | Minority |
MirimGENE FAQs
-
When was MirimGENE founded?
MirimGENE was founded in 2019.
-
Where is MirimGENE headquartered?
MirimGENE is headquartered in Incheon, South Korea.
-
What is the size of MirimGENE?
MirimGENE has 3 total employees.
-
What industry is MirimGENE in?
MirimGENE’s primary industry is Drug Discovery.
-
Is MirimGENE a private or public company?
MirimGENE is a Private company.
-
What is MirimGENE’s current revenue?
The current revenue for MirimGENE is .
-
How much funding has MirimGENE raised over time?
MirimGENE has raised $7.56M.
-
Who are MirimGENE’s investors?
Honest Ventures, KDB Capital, L&S Venture Capital, Magna Investment (Seoul), and Samho Green Investment are 5 of 7 investors who have invested in MirimGENE.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process